Novel light-sensitive drug induces sleep without genetic modification

FHS
May 28, 2024
5:41 pm

The nucleus accumbens plays a pivotal role in motivational behavior and sleep regulation, modulated by adenosine A2A receptors (A2AR).

Navigating STXBP1-related disorders: Unraveling clinical and developmental outcomes

Researchers examined the combined patient-years of seizure and developmental histories in individuals with disorders related to the STXBP1 gene.

December 4, 2023

MindMed Reports Third Quarter 2024 Financial Results and Business Updates | Psychedelic Invest

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced

November 7, 2024

FDA scolds Novartis over a misleading TV ad for a breast cancer treatment

The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about a best-selling breast cancer treatment in a television ad in

January 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.